Протективный потенциал ингибиторов натрий-глюкозного котранспортера 2 типа в клинике внутренних болезней (часть 1)

Ингибиторы натрий-глюкозного котранспортера 2 типа (SGLT2i) вошли в клиническую практику как революционный класс пероральных сахаропонижающих препаратов. По мере накопления клинических данных были обнаружены их долговременные защитные эффекты в отношении многих органов и тканей. Защитный потенциал SGLT2i гораздо шире, чем классическая концепция контроля глюкозы и состоит из целого конгломерата плейотропных эффектов.

Целью данной статьи является предоставление описательного обзора плейотропного терапевтического потенциала SGLT2i. В первой части обзора литературы рассматривается использование SGLT2i в кардиологии и нефрологии.

Таким образом, использование SGLT2i представляет собой инновационный подход к улучшению качества жизни пациентов и течения как сердечной недостаточности, так и хронической болезни почек, независимо от фракции выброса левого желудочка и наличия сахарного диабета 2 типа.

1. Idowu A, Adebolu O, Wattanachayakul P, et al. Cardiovascular outcomes of sodium-glucose Co-transporter 2 inhibitors use after myocardial infarction: a systematic review and meta-analysis of randomized controlled trials. Curr Probl Cardiol. 2024;49(8):102648. PMID: 38759767. https://doi.org/10.1016/j.cpcardiol.2024.102648

2. Patoulias D. SGLT-2 inhibitors beneficial effects on ventricular repolarization may be protective against atrial fibrillation occurrence. Acta Cardiol Sin. 2021;37(3):323. PMID: 33976519. PMCID: PMC8107699. https://doi.org/10.6515/ACS.202105_37(3).20210313A

3. Jasleen B, Vishal GK, Sameera M, et al. Sodium-glucose cotransporter 2 (SGLT2) inhibitors: benefits versus risk. Cureus. 2023;15(1):e33939. PMID: 36819350. PMCID: PMC9937770. https://doi.org/10.7759/cureus.33939

4. Терещенко С.Н., Шестакова М.В., Агеев Ф.Т. и др. Целесообразность назначения дапаглифлозина для профилактики неблагоприятных исходов хронической сердечной недостаточности у пациентов со сниженной фракцией выброса. Резолюция совета экспертов. Российский кардиологический журнал. 2020;25(5):3919. https://doi.org/10.15829/1560-4071-2020-3919

5. Кобалава Ж.Д., Лазарев П.В., Виллевальде С.В. ингибиторы SGLT2: обоснование и перспективы применения при сердечной недостаточности. Кардиология. 2018;58(2):42–54. PMID: 29466200. https://doi.org/10.18087/cardio.2018.2.10087

6. Faluk M, Wardhere A, Thakker R, Khan FA. SGLT2 inhibitors in heart failure with preserved ejection fraction. Curr Probl Cardiol. 2024;49(3):102388. PMID: 38184133. https://doi.org/10.1016/j.cpcardiol.2024.102388

7. Avagimyan A, Sheibani M, Pogosova N, et al. Possibilities of dapagliflozin-induced cardioprotection on doxorubicin + cyclophosphamide mode of chemotherapy-induced cardiomyopathy. Int J Cardiol. 2023;391:131331. PMID: 37666280. https://doi.org/10.1016/j.ijcard.2023.131331

8. Gajewska A, Wasiak J, Sapeda N, Młynarska E, Rysz J, Franczyk B. SGLT2 inhibitors in kidney diseases-a narrative review. Int J Mol Sci. 2024;25(9):4959. PMID: 38732178. PMCID: PMC11084583. https://doi.org/10.3390/ijms25094959

9. Rizzo MR, Di Meo I, Polito R, et al. Cognitive impairment and type 2 diabetes mellitus: focus of SGLT2 inhibitors treatment. Pharmacol Res. 2022;176:106062. PMID: 35017046. https://doi.org/10.1016/j.phrs.2022.106062

10. Sun M, Sun J, Sun W, et al. Unveiling the anticancer effects of SGLT-2i: mechanisms and therapeutic potential. Front Pharmacol. 2024;15:1369352. PMID: 38595915. PMCID: PMC11002155. https://doi.org/10.3389/fphar.2024.1369352

11. Zhou B, Shi Y, Fu R, et al. Relationship between SGLT-2i and ocular diseases in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials. Front Endocrinol (Lausanne). 2022;13:907340. PMID: 35692406. PMCID: PMC9178099. https://doi.org/10.3389/fendo.2022.907340

12. Бойцов С.А., Погосова Н.В., Аншелес А.А. и др. Кардиоваскулярная профилактика 2022. Российские национальные рекомендации. Российский кардиологический журнал. 2023;28(5):5452. https://doi.org/10.15829/1560-4071-2023-5452

13. Погосова Н.В., Бойцов С.А. Профилактическая кардиология 2024: состояние проблемы и перспективы развития. Кардиология. 2024;64(1):4–13. PMID: 38323439. https://doi.org/10.18087/cardio.2024.1.n2636

14. Eghøj M, Zinckernagel L, Brinks T, et al. Adapting an evidence-based, home cardiac rehabilitation programme for people with heart failure and their caregivers to the Danish context: DK:REACH-HF study. Eur J Cardiovasc Nurs. Published online March 25, 2024. PMID: 38526240. https://doi.org/10.1093/eurjcn/zvae037

15. Bhanushali KB, Asnani HK, Nair A, Ganatra S, Dani SS. Pharmacovigilance study for SGLT 2 inhibitors – safety review of real-world data & randomized clinical trials. Curr Probl Cardiol. 2024;49(9):102664. PMID: 38789017. https://doi.org/10.1016/j.cpcardiol.2024.102664

16. Cunningham C, Jabri A, Alhuneafat L, Aneja A. A comprehensive guide to sodium glucose cotransport inhibitors. Curr Probl Cardiol. 2023;48(10):101817. PMID: 37211299. https://doi.org/10.1016/j.cpcardiol.2023.101817

17. He Z, Yang L, Nie Y, et al. Effects of SGLT-2 inhibitors on health-related quality of life and exercise capacity in heart failure patients with reduced ejection fraction: a systematic review and meta-analysis. Int J Cardiol. 2021;345:83–88. PMID: 34653575. https://doi.org/10.1016/j.ijcard.2021.10.008

18. Crisman E, Duarte P, Dauden E, et al. KEAP1-NRF2 protein-protein interaction inhibitors: design, pharmacological properties and therapeutic potential. Med Res Rev. 2023;43(1):237–287. PMID: 36086898. PMCID: PMC10087726. https://doi.org/10.1002/med.21925

19. Zhang H, Davies KJA, Forman HJ. Oxidative stress response and Nrf2 signaling in aging. Free Radic Biol Med. 2015;88(Pt B):314–336. PMID: 26066302. PMCID: PMC4628850. https://doi.org/10.1016/j.freeradbiomed.2015.05.036

20. Cheng PP, Wang XT, Liu Q, et al. Nrf2 mediated signaling axis in heart failure: potential pharmacological receptor. Pharmacol Res. 2024;206:107268. PMID: 38908614. https://doi.org/10.1016/j.phrs.2024.107268

21. Lu MC, Ji JA, Jiang ZY, You QD. The Keap1-Nrf2-ARE pathway as a potential preventive and therapeutic target: an update. Med Res Rev. 2016;36(5):924–963. PMID: 27192495. https://doi.org/10.1002/med.21396

22. Lu Y, An L, Taylor MRG, Chen QM. Nrf2 signaling in heart failure: expression of Nrf2, Keap1, antioxidant, and detoxification genes in dilated or ischemic cardiomyopathy. Physiol Genomics. 2022;54(3):115–127. https://doi.org/10.1152/physiolgenomics.00079.2021

23. Chen YY, Wu TT, Ho CY, et al. Blocking of SGLT2 to eliminate NADPH-induced oxidative stress in lenses of animals with fructose-induced diabetes mellitus. Int J Mol Sci. 2022;23(13):7142. PMID: 35806147. PMCID: PMC9266761. https://doi.org/10.3390/ijms23137142

24. Massagué J, Sheppard D. TGF-β signaling in health and disease. Cell. 2023;186(19):4007–4037. PMID: 37714133. PMCID: PMC10772989. https://doi.org/10.1016/j.cell.2023.07.036

25. Hata A, Chen YG. TGF-β signaling from receptors to smads. Cold Spring Harb Perspect Biol. 2016;8(9):a022061. PMID: 27449815. PMCID: PMC5008074. https://doi.org/10.1101/cshperspect.a022061

26. Fatehi Hassanabad A, Zarzycki A, Fedak PWM. Cellular and molecular mechanisms driving cardiac tissue fibrosis: on the precipice of personalized and precision medicine. Cardiovasc Pathol. 2024;71:107635. PMID: 38508436. https://doi.org/10.1016/j.carpath.2024.107635

27. Giordano C, Francone M, Cundari G, Pisano A, d’Amati G. Myocardial fibrosis: morphologic patterns and role of imaging in diagnosis and prognostication. Cardiovasc Pathol. 2022;56:107391. PMID: 34601072. https://doi.org/10.1016/j.carpath.2021.107391

28. Gager GM, von Lewinski D, Sourij H, et al. Effects of SGLT2 inhibitors on ion homeostasis and oxidative stress associated mechanisms in heart failure. Biomed Pharmacother. 2021;143:112169. PMID: 34560555. https://doi.org/10.1016/j.biopha.2021.112169

29. Kume S, Packer M. SGLT2 inhibitors act as metabolic transducers to restore healthy nutrient deprivation and surplus signaling in the kidney. Kidney Int. 2024;105(6):1172–1176. PMID: 38777403. https://doi.org/10.1016/j.kint.2024.01.044

30. Packer M. Critical reanalysis of the mechanisms underlying the cardiorenal benefits of SGLT2 inhibitors and reaffirmation of the nutrient deprivation signaling/autophagy hypothesis. Circulation. 2022;146(18):1383–1405. PMID: 36315602. PMCID: PMC9624240. https://doi.org/10.1161/CIRCULATIONAHA.122.061732

31. Stachteas P, Karakasis P, Patoulias D, Clemenza F, Fragakis N, Rizzo M. The effect of sodium-glucose co-transporter-2 inhibitors on markers of subclinical atherosclerosis. Ann Med. 2023;55(2):2304667. PMID: 38233735. PMCID: PMC10798275. https://doi.org/10.1080/07853890.2024.2304667

32. Gaspari T, Spizzo I, Liu H, et al. Dapagliflozin attenuates human vascular endothelial cell activation and induces vasorelaxation: a potential mechanism for inhibition of atherogenesis. Diab Vasc Dis Res. 2018;15(1):64–73. Published correction appears in Diab Vasc Dis Res. 2018;15(4):364. PMID: 28976221. https://doi.org/10.1177/1479164117733626

33. Wiviott SD, Raz I, Bonaca MP, et al; DECLARE–TIMI 58 Investigators. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347–357. PMID: 30415602. https://doi.org/10.1056/NEJMoa1812389

34. McMurray JJV, Solomon SD, Inzucchi SE, et al; DAPA-HF Trial Committees and Investigators. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995–2008. PMID: 31535829. https://doi.org/10.1056/NEJMoa1911303

35. Solomon SD, McMurray JJV, Claggett B, et al; DELIVER Trial Committees and Investigators. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;387(12):1089–1098. PMID: 36027570. https://doi.org/10.1056/NEJMoa2206286

36. Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al; DAPA-CKD Trial Committees and Investigators. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436–1446. PMID: 32970396. https://doi.org/10.1056/NEJMoa2024816

37. Borlaug BA, Reddy YNV, Braun A, et al. Cardiac and metabolic effects of dapagliflozin in heart failure with preserved ejection fraction: the CAMEO-DAPA trial. Circulation. 2023;148(10):834–844. PMID: 37534453. PMCID: PMC10529848. https://doi.org/10.1161/CIRCULATIONAHA.123.065134

38. Nassif ME, Windsor SL, Borlaug BA, et al. The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial. Nat Med. 2021;27(11):1954–1960. PMID: 34711976. PMCID: PMC8604725. https://doi.org/10.1038/s41591-021-01536-x

39. Scholtes RA, Muskiet MHA, van Baar MJB, et al. Natriuretic effect of two weeks of dapagliflozin treatment in patients with type 2 diabetes and preserved kidney function during standardized sodium intake: results of the DAPASALT trial. Diabetes Care. 2021;44(2):440–447. PMID: 33318125. PMCID: PMC7818331. https://doi.org/10.2337/dc20-2604

40. Heerspink HJL, Oshima M, Zhang H, et al. Canagliflozin and kidney-related adverse events in type 2 diabetes and CKD: findings from the randomized CREDENCE trial. Am J Kidney Dis. 2022;79(2):244–256.e1. PMID: 34029680. https://doi.org/10.1053/j.ajkd.2021.05.005

41. Packer M, Anker SD, Butler J, et al. Effect of empagliflozin on the clinical stability of patients with heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial. Circulation. 2021;143(4):326–336. Published correction appears in Circulation. 2021;143(4):e30. PMID: 33081531. PMCID: PMC7834905. https://doi.org/10.1161/CIRCULATIONAHA.120.051783

42. Packer M, Butler J, Zannad F, et al. Effect of empagliflozin on worsening heart failure events in patients with heart failure and preserved ejection fraction: EMPEROR-Preserved trial. Circulation. 2021;144(16):1284–1294. PMID: 34459213. PMCID: PMC8522627. https://doi.org/10.1161/CIRCULATIONAHA.121.056824

43. Bhatt DL, Szarek M, Steg PG, et al; SOLOIST-WHF Trial Investigators. Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med. 2021;384(2):117–128. PMID: 33200892. https://doi.org/10.1056/NEJMoa2030183

44. Perkovic V, de Zeeuw D, Mahaffey KW, et al. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials. Lancet Diabetes Endocrinol. 2018;6(9):691–704. PMID: 29937267. https://doi.org/10.1016/S2213-8587(18)30141-4

45. Zinman B, Wanner C, Lachin JM, et al; EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–2128. PMID: 26378978. https://doi.org/10.1056/NEJMoa1504720

46. Cannon CP, Pratley R, Dagogo-Jack S, et al; VERTIS CV Investigators. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med. 2020;383(15):1425–1435. PMID: 32966714. https://doi.org/10.1056/NEJMoa2004967

47. Bhatt DL, Szarek M, Pitt B, et al; SCORED Investigators. Sotagliflozin in patients with diabetes and chronic kidney disease. N Engl J Med. 2021;384(2):129–139. PMID: 33200891. https://doi.org/10.1056/NEJMoa2030186

48. Mansouri MH, Mansouri P, Sadeghi M, et al. Antianginal effects of empagliflozin in patients with type 2 diabetes and refractory angina; a randomized, double-blind placebo-controlled trial (EMPT-ANGINA Trial). Clin Cardiol. 2024;47(1):e24158. PMID: 37721420. PMCID: PMC10766003. https://doi.org/10.1002/clc.24158

49. Xie L, Li S, Yu X, Wei Q, Yu F, Tong J. DAHOS study: efficacy of dapagliflozin in treating heart failure with reduced ejection fraction and obstructive sleep apnea syndrome - a 3-month, multicenter, randomized controlled clinical trial. Eur J Clin Pharmacol. 2024;80(5):771–780. PMID: 38386021. https://doi.org/10.1007/s00228-024-03643-3

50. James S, Erlinge D, Storey RF, et al. Dapagliflozin in myocardial infarction without diabetes or heart failure. NEJM Evid. 2024;3(2):EVIDoa2300286. PMID: 38320489. https://doi.org/10.1056/EVIDoa2300286

51. Giaccari A, Pontremoli R, Perrone Filardi P. SGLT-2 inhibitors for treatment of heart failure in patients with and without type 2 diabetes: a practical approach for routine clinical practice. Int J Cardiol. 2022;351:66–70. PMID: 34979145. https://doi.org/10.1016/j.ijcard.2021.12.050

52. Курашин В.К., Боровкова Н.Ю., Курашина В.А., Бакка Т.Е. Возможности кардио- и нефропротективного действия препаратов группы ингибиторов SGLT2. Клиническая медицина. 2021;99(3):172–176. https://doi.org/10.30629/0023-2149-2021-99-3-172-176

53. Woo V, Connelly K, Lin P, McFarlane P. The role of sodium glucose cotransporter-2 (SGLT-2) inhibitors in heart failure and chronic kidney disease in type 2 diabetes. Curr Med Res Opin. 2019;35(7):1283–1295. PMID: 30767677. https://doi.org/10.1080/03007995.2019.1576479

54. Bülow RD, Boor P. Extracellular matrix in kidney fibrosis: more than just a scaffold. J Histochem Cytochem. 2019;67(9):643–661. PMID: 31116062. PMCID: PMC6713975. https://doi.org/10.1369/0022155419849388

55. Wang Y, Jin M, Cheng CK, Li Q. Tubular injury in diabetic kidney disease: molecular mechanisms and potential therapeutic perspectives. Front Endocrinol (Lausanne). 2023;14:1238927. PMID: 37600689. PMCID: PMC10433744. https://doi.org/10.3389/fendo.2023.1238927

56. Sarafidis P, Ortiz A, Ferro CJ, et al; ‘Hypertension and the Kidney’ working group of the European Society of Hypertension (ESH) and the ‘European Renal and Cardiovascular Medicine’ (EURECA-m) working group of the European Renal Association. Sodium--glucose co-transporter-2 inhibitors for patients with diabetic and nondiabetic chronic kidney disease: a new era has already begun. J Hypertens. 2021;39(6):1090–1097. PMID: 33443971. https://doi.org/10.1097/HJH.0000000000002776

57. Thomson SC, Vallon V. Renal effects of sodium-glucose co-transporter inhibitors. Am J Cardiol. 2019;124 Suppl 1(Suppl 1):S28–S35. PMID: 31741437. PMCID: PMC7258222. https://doi.org/10.1016/j.amjcard.2019.10.027

58. Skrabic R, Kumric M, Vrdoljak J, et al. SGLT2 inhibitors in chronic kidney disease: from mechanisms to clinical practice. Biomedicines. 2022;10(10):2458. PMID: 36289720. PMCID: PMC9598622. https://doi.org/10.3390/biomedicines10102458

59. Di Costanzo A, Esposito G, Indolfi C, Spaccarotella CAM. SGLT2 inhibitors: a new therapeutical strategy to improve clinical outcomes in patients with chronic kidney diseases. Int J Mol Sci. 2023;24(10):8732. PMID: 37240080. PMCID: PMC10218404. https://doi.org/10.3390/ijms24108732

60. Корбут А.И., Климонтов В.В. Эмпаглифлозин: новая стратегия нефропротекции при сахарном диабете. Сахарный диабет. 2017;20(1):75–84. https://doi.org/10.14341/dm8005

61. Сухарева О.Ю., Зураева З.Т., Шамхалова М.Ш. Актуализация позиций глифлозинов в алгоритмах лечения пациентов с сахарным диабетом 2 типа и хронической болезнью почек: новые патогенетические механизмы и данные субанализов крупных рандомизированных контролируемых исследований. Сахарный диабет. 2021;24(6):553–564. https://doi.org/10.14341/dm12864

62. Mark PB, Sarafidis P, Ekart R, et al. SGLT2i for evidence-based cardiorenal protection in diabetic and non-diabetic chronic kidney disease: a comprehensive review by EURECA-m and ERBP working groups of ERA. Nephrol Dial Transplant. 2023;38(11):2444–2455. PMID: 37230946. PMCID: PMC10615631. https://doi.org/10.1093/ndt/gfad112

63. Gérard AO, Laurain A, Favre G, Drici MD, Esnault VLM. Activation of the tubulo-glomerular feedback by SGLT2 inhibitors in patients with type 2 diabetes and advanced chronic kidney disease: toward the end of a myth?. Diabetes Care. 2022;45(10):e148–e149. PMID: 35973076. PMCID: PMC9862288. https://doi.org/10.2337/dc22-0921

64. Kim NH, Kim NH. Renoprotective mechanism of sodium-glucose cotransporter 2 inhibitors: focusing on renal hemodynamics. Diabetes Metab J. 2022;46(4):543–551. PMID: 35929172. PMCID: PMC9353563. https://doi.org/10.4093/dmj.2022.0209

65. Wang Q, Yu J, Deng W, et al. Influence of sodium/glucose cotransporter-2 inhibitors on the incidence of acute kidney injury: a meta-analysis. Front Pharmacol. 2024;15:1372421. PMID: 38983922. PMCID: PMC11231204. https://doi.org/10.3389/fphar.2024.1372421

66. Nespoux J, Vallon V. Renal effects of SGLT2 inhibitors: an update. Curr Opin Nephrol Hypertens. 2020;29(2):190–198. PMID: 31815757. PMCID: PMC7224333. https://doi.org/10.1097/MNH.0000000000000584

67. Cleveland KH, Schnellmann RG. Pharmacological targeting of mitochondria in diabetic kidney disease. Pharmacol Rev. 2023;75(2):250–262. PMID: 36781216. https://doi.org/10.1124/pharmrev.122.000560

68. Mulder S, Heerspink HJL, Darshi M, et al. Effects of dapagliflozin on urinary metabolites in people with type 2 diabetes. Diabetes Obes Metab. 2019;21(11):2422–2428. PMID: 31264758. https://doi.org/10.1111/dom.13823

69. Lee YH, Kim SH, Kang JM, et al. Empagliflozin attenuates diabetic tubulopathy by improving mitochondrial fragmentation and autophagy. Am J Physiol Renal Physiol. 2019;317(4):F767–F780. PMID: 31390268. https://doi.org/10.1152/ajprenal.00565.2018

70. Chun Y, Kim J. AMPK-mTOR signaling and cellular adaptations in hypoxia. Int J Mol Sci. 2021;22(18):9765. PMID: 34575924. PMCID: PMC8465282. https://doi.org/10.3390/ijms22189765

71. Podestà MA, Sabiu G, Galassi A, Ciceri P, Cozzolino M. SGLT2 inhibitors in diabetic and non-diabetic chronic kidney disease. Biomedicines. 2023;11(2):279. PMID: 36830815. PMCID: PMC9953060. https://doi.org/10.3390/biomedicines11020279

72. Fernandez-Fernandez B, Sarafidis P, Kanbay M, et al. SGLT2 inhibitors for non-diabetic kidney disease: drugs to treat CKD that also improve glycaemia. Clin Kidney J. 2020;13(5):728–733. PMID: 33123352. PMCID: PMC7577767. https://doi.org/10.1093/ckj/sfaa198

73. Neal B, Perkovic V, Mahaffey KW, et al; CANVAS Program Collaborative Group. Canagliflozin and Cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644–657. PMID: 28605608. https://doi.org/10.1056/NEJMoa1611925

74. Packer M, Anker SD, Butler J, et al; EMPEROR-Reduced Trial Investigators. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413–1424. PMID: 32865377. https://doi.org/10.1056/NEJMoa2022190

75. Chang YK, Choi H, Jeong JY, et al. Dapagliflozin, SGLT2 inhibitor, attenuates renal ischemia-reperfusion injury. PLoS One. 2016;11(7):e0158810. Published correction appears in PLoS One. 2016;11(7):e0160478. PMID: 27391020. PMCID: PMC4938401. https://doi.org/10.1371/journal.pone.0158810

76. Zhang Y, Nakano D, Guan Y, et al. A sodium-glucose cotransporter 2 inhibitor attenuates renal capillary injury and fibrosis by a vascular endothelial growth factor-dependent pathway after renal injury in mice. Kidney Int. 2018;94(3):524–535. PMID: 30045814. https://doi.org/10.1016/j.kint.2018.05.002